Lilly signs voluntary licensing agreement with Natco for baricitinib

Eli Lilly and Company announced that it has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma.

Lilly received permission for restricted emergency use by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for baricitinib to be used in combination with remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Lilly had also announced the signing of six Voluntary License Agreements with Cipla, Lupin, Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, MSN Laboratories and Torrent Pharmaceuticals, to further ensure equitable access of baricitinib for people who are currently impacted by the burden of COVID-19.